News & Events
September 17, 2018
Critical Path Institute and SIGNATOPE GmbH Team Up to Advance Research on Biomarkers for Drug-induced Organ InjuriesTUCSON, Ariz. and REUTLINGEN, September 17, 2018 — Critical Path Institute’s Predictive Safety Testing Consortium (PSTC) and SIGNATOPE GmbH are excited to announce a new project, joining efforts on analyzing and qualifying promising protein safety biomarkers in mouse, rat, dog, monkey, and human. The work is expected to increase understanding of drug-induced toxicities...
September 6, 2018
Doris Duke Charitable Foundation Awards Grant to Critical Path Institute to Advance Therapies for Sickle Cell DiseaseContacts: Kissy Black, Critical Path Institute [email protected], 615.298.1144 Kristin Roth-Schrefer, Communications Director [email protected], 212.974.7003 Nina Chung, Communications Associate [email protected], 212.974.7006 Critical Path Institute (C-Path) Will Plan a Consortium of Stakeholders Focused on Developing Therapies for Sickle Cell Disease NEW YORK, September 6, 2018 — In a continuing effort to spur advancements in treating...
July 26, 2018
First-ever biomarker qualified for Parkinson’s is a vital step toward improved clinical trialsFOR IMMEDIATE RELEASE Contact: Kissy Black 615.298.1144 [email protected] Tucson, AZ — July 26, 2018 – The Critical Path Institute’s (C-Path) Critical Path for Parkinson’s Consortium (CPP), in partnership with Parkinson’s UK, announces that the European Medicines Agency (EMA) has issued a positive qualification opinion on an imaging test (biomarker) as a tool to enrich...
May 7, 2018
C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ)TUCSON, Ariz. – May 7, 2018 — Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its second clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA). The qualification of the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) for exploratory use represents another major milestone for the PRO Consortium and, specifically,...
April 16, 2018
Helmsley Charitable Trust Awards Critical Path Institute a Grant to Focus on Crohn’s Disease BiomarkersTucson, AZ, and New York, NY – April 16, 2018 — The Leona M. and Harry B. Helmsley Charitable Trust has awarded Critical Path Institute (C-Path) a grant to support a Crohn’s disease biomarker pre-consortium. The pre-consortium will identify unmet needs for the use of biomarkers in developing new treatments for people with Crohn’s disease. Currently,...